Meropur

Menotropin, the active ingredient in Meropur, is a gonadotropin presented as a sterile solution for subcutaneous use. It provides combined FSH and LH activity to treat infertility due to anovulation and to support assisted reproductive technology protocols in women.

GNH USA supplies Meropur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution, ensuring product integrity from manufacturing to end‑user.

Meropur (menotropin) is used in fertility treatment to stimulate ovarian follicular development.

Infertility due to anovulation: stimulates follicular growth and induces ovulation in women who do not ovulate spontaneously. Assisted reproductive technology (ART) cycles: enhances controlled ovarian stimulation for procedures such as IVF. In vitro fertilization (IVF) treatment: increases the number of mature oocytes retrieved during egg collection.

Menotropin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Abdominal bloating or discomfort - Headache - Nausea or mild gastrointestinal upset

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy - Severe allergic reaction (anaphylaxis) - Thromboembolic events

When using Menotropin, clinicians should observe several safety considerations to minimize risks.

Monitor ovarian response: perform ultrasound and estradiol measurements to adjust dose. Avoid use in pregnancy: the drug is intended for pre‑conception ovarian stimulation. Use cautiously in hormone‑sensitive cancers: FSH/LH may stimulate tumor growth. Assess for ovarian cysts: pre‑existing cysts increase risk of complications. Adjust dose in renal or hepatic impairment: consider reduced dosing and close monitoring. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotropin can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other gonadotropins: may cause excessive ovarian stimulation. - Estrogen‑containing oral contraceptives during stimulation: can blunt response and increase OHSS risk. - Simultaneous GnRH agonist therapy: may lead to unpredictable hormone levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased risk of ovarian bleeding. - Corticosteroids: may alter hormone metabolism. - Thyroid hormone replacement: monitor thyroid function as ovarian activity changes.